If you continue to take the drug, it will remain in your system and prolong the elimination period
Early separation of the curves demonstrates the role of oral semaglutide in people with type 2 diabetes and high cardiovascular risk, said Rodica Pop-Busui, MD, PhD, the Jordan Schnitzer Endowed Chair in Diabetes, Professor and Head of Endocrinology and Diabetes, and Director of the Harold Schnitzer Diabetes Center at Oregon Health & Sciences University, during the Sunday, June 22, symposium, SOUL TrialEffects of Oral Semaglutide on Cardiovascular (and Other) Outcomes in People with Type 2 Diabetes at High CV Risk
Trusted by Las Vegas patients for over 30 years
For individuals managing chronic back pain, it is critical to weigh these potential risks with the benefits of the medication
Find out if you may be able to take action during a free case review now